Stelara Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque Psoriasis

CHICAGO, Aug. 9 /PRNewswire/ -- New study findings showed that a
majority of patients with moderate to severe plaque psoriasis who
had a previous response to STELARA® (ustekinumab) sustained a
clinical response for up to three years with...